L-Histidinol (hydrochloride)
(Synonyms: L-组氨醇二盐酸盐,(S)-Histidinol) 目录号 : GC16438An intermediate in L-histidine biosynthesis
Cas No.:1596-64-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
L-Histidinol is an intermediate in the biosynthesis of the amino acid L-histidine.
L-Histidine biosynthesis is a metabolic pathway present in bacteria, archaea, lower eukaryotes, as well as plants. L-histidine biosynthesis has been studied mainly in Escherichia coli and Salmonella typhimurium, revealing fundamental regulatory processes in bacteria.
In vitro: Preliminary experiments were done to investigate the cytotoxic effect of L-histidinol on cultured EAC cells. Results showed that L-histidinol up to 4 mM had no cytotoxic effects on EAC cells. Doxorubicin alone showed concentration-dependent cytotoxic effects. L-Histidinol combination with doxorubicin led to significant potentiation of doxorubicin cytotoxicity to EAC cells compared to doxorubicin alone. The concentration that caused 50% growth inhibition in EAC cells after 24 h incubation was about 0.2 μg/ml, whereas it was 0.1 μg/ml when L-histidinol was added to culture medium [1].
In vivo: L-Histidinol at 250 mg/kg for five consecutive doses before doxorubicin single injection could enhance the antitumour activity of doxorubicin in EAC-bearing mice as demonstrated by a significant increase in average life span and cure rate of mice. In normal mice, L-histidinol, in the same dose regimen, could not alter the acute cardiotoxicity and lethality of doxorubicin [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Al-Shabanah OA, Badary OA, Al-Gharably NM, Al-Sawaf HA. Effects of L-histidinol on the antitumour activity and acute cardiotoxicity of doxorubicin in mice. Pharmacol Res. 1998 Sep;38(3):225-30.
Cas No. | 1596-64-1 | SDF | |
别名 | L-组氨醇二盐酸盐,(S)-Histidinol | ||
化学名 | (βS)-amino-1H-imidazole-5-propanol, dihydrochloride | ||
Canonical SMILES | OC[C@@H](N)CC1=CNC=N1.Cl.Cl | ||
分子式 | C6H11N3O • 2HCl | 分子量 | 214.1 |
溶解度 | ≤5mg/ml in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.6707 mL | 23.3536 mL | 46.7071 mL |
5 mM | 0.9341 mL | 4.6707 mL | 9.3414 mL |
10 mM | 0.4671 mL | 2.3354 mL | 4.6707 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。